1,2,3-Tri-O-Acetyl-5-Deoxy-D-Ribofuranose

62211-93-2

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-o'riented and realizes industrial development through R&‍;D innovation and technology transformation.

key word:

technology Pharmaceutical

Category:

Intermediate

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to builσd a large health industry finance platform company integrating p×harmaceutical, intelligent medical, bio pharmaceutical R&D, industrial ←production and sales.

The chemical reactions involved in the existing products include Foucault reaction, nitration rea>ction, sulfonation reaction, hydrogenation reaction, fluorination reaction, chlorinat£ion reaction, bromination reaction, diazotization reaction, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor de≤veloped by Merck. In October 2006, Sitagliptin phosphate Januvia was→ approved by FDA as the first DPP4 inhibitor for the  treatment of type ⅱ diabetes mellitus. The characteristics of this dru↔g are that it can stimulate insulin secretion while r€educing hunger without causing weight gain. Hypoglycφemia and edema will not occur, and it is suitable for diabetic patients with poor blood glεucose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceu€tical enterprise that is market-oriented and realizes industrial development tαhrough R&D innovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most important pλroducts for the treatment of arthritis. It is well tolerated and has a low incidence ☆of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor antagonists. In cl​inical application, it has good therapeutic effect on atopic$ asthma and other types of bronchial asthma, and the market prospect is huge. In the major÷ category of asthma drugs, leukotriene receptor antagonists have the fas£test growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is ma∑rket-oriented and realizes industrial development through R&D innovation and technolog♣y transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approved by FDA" for Alzheimer's disease in the United States. Its treatment rδeaches the target dose and has low toxic and side effects. It has been widely reco•gnized by our medical community, and good tolerance is its biggest advantage. In OcΩtober 1999, Donepezil was launched in China under the trade name "Arice↕pt", which is the main chemical drug against Alzheimer's disease. At present, CFDA has< approved a number of domestic enterprises to produce donepezil preparations, the main dosage forms‍ are tablets, capsules, dispersive tablets, oral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bλristol-Myers Squibb/Pfizer), a direct oral factor Xa inhibitor, was approved for ≈use in the 27 EU member states. The world's first drug approved to prevent venous thromboembolism  (VTE) in adult patients undergoing elective hip or knee replacement. From June 2019 to June↕ 2020, the annual sales of apixaban products overseas reached about $15.4 bil©lion, with a year-on-year growth of nearly 32%, and the API consumption reache&d about 23,960 kg, with a year-on-year growth of about 28%. Compared with its main competitor, Rivσaroxaban, the drug's annual overseas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-orient↓ed and realizes industrial development through R&D innovation and technology transf‌ormation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzym£e. On December 29, 2004, it was approved by FDA for the treatment of refractory or relapsed a§cute lymphoblastic leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical e¥nterprise that is market-oriented and realizes industrial development through R&D ‌innovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you need other →services, E-mail: 2880705932@qq.com